文献速递肾癌与肾肿瘤

机器人辅助内镜下简单剜除术与腹腔镜简单剜除术治疗局限性肾肿瘤的倾向性评分匹配分析

Endoscopic Robot-assisted Simple Enucleation Versus Laparoscopic Simple Enucleation With Single-layer Renorrhaphy in Localized Renal Tumors: A Propensity Score-matched Analysis From a High-volume Centre.
PubMed 文献 · Urology · 2018-08-28

本研究通过倾向性评分匹配比较了机器人辅助内镜下简单剜除术(ERASE)与腹腔镜简单剜除术(LSE)治疗局限性肾肿瘤的围手术期结果和早期肿瘤学结局。匹配后ERASE组手术时间和热缺血时间显著更短,术中并发症发生率更低,而估计出血量、中转开放或根治性肾切除术率、切缘阳性率及复发率两组相似。结论认为ERASE是LSE安全可接受的替代方案。

要点

  • ERASE较LSE手术时间更短(171.9 vs 188.2分钟,P=0.016)。

核心结论

  • ERASE是LSE安全可接受的替代方案,具有更短的手术时间和热缺血时间以及更低的术中并发症发生率。

研究设计与样本

  • 匹配变量包括年龄、性别、体重指数、ECOG评分、肿瘤侧别和大小、术前eGFR及PADUA评分。
  • 匹配后ERASE组278例,LSE组105例。

临床怎么用

  • 对于局限性肾肿瘤,ERASE可作为LSE的替代选择,尤其关注缩短手术时间和热缺血时间以及降低术中并发症。

局限性

  • ERASE组中位随访时间短于LSE组(22 vs 38个月),早期肿瘤学结局需更长期随访验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare perioperative results and early oncological outcomes of endoscopic robot-assisted simple enucleation (ERASE) and laparoscopic simple enucleation (LSE) by using a propensity score-matched analysis. METHODS: We evaluated 383 patients who underwent transperitoneal ERASE or LSE for renal tumors from November 2012 to October 2016. Propensity score matching was performed on age, gender, body mass index, Eastern Cooperative Oncology Group score, tumor side and size, preoperative estimated GFR and PADUA score. RESULTS: In total, 278 and 105 patients underwent ERASE and LSE, respectively. The PADUA score was ≥10 for 61 (21.9%) and 13 (12.4%), respectively (P = .034). After matching, mean operative time and warm ischemic time were significantly lower with ERASE than LSE (171.9 vs 188.2 minutes; P = 0.016 and 20.9 vs 24.2 minutes; P = .001). The estimated mean blood loss was similar (167.7 vs 183.3 mL; P = .315). The conversion rate to open surgery or radical nephrectomy was similar with ERASE and LSE (1.0% vs 5.0%, P = .214) and the rate of intraoperative complications was lower (2.0% vs 8.9%, P = .030). The overall incidence of positive surgical margins was similar (P = .614). The median follow-up was less for ERASE than LSE patients (22 vs 38 months). Recurrence did not differ between the 2 groups: 2 ERASE cases (2.0%) versus 4 LSE cases (4.0%) (P = .679). CONCLUSION: ERASE is a safe and acceptable alternative to LSE. ERASE appears to confer shorter operative time, shorter warm ischemic time and lower rate of intraoperative complication.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Zhao X, Lu Q, Campi R, et al. Endoscopic Robot-assisted Simple Enucleation Versus Laparoscopic Simple Enucleation With Single-layer Renorrhaphy in Localized Renal Tumors: A Propensity Score-matched Analysis From a High-volume Centre. Urology. 2018. PMID: 30170093. doi:10.1016/j.urology.2018.08.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。